Anthrax -- Canada
Emergent BioSolutions Inc. (NYSE:EBS) today [Mon 17 Dec 2018] announced that Health Canada has approved the company's new drug submission (NDS) for its anthrax vaccine, BioThrax (anthrax vaccine adsorbed). BioThrax is indicated for active immunization for the prevention of disease caused by _Bacillus anthracis_ in individuals 18 through 65 years of age whose occupation or other activities place them at risk of exposure, regardless of the route of exposure. BioThrax is administered in a 3-dose
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?6214289&promed&0
No comments:
Post a Comment